Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Levine
    Levine
  2. Koche
    Koche
  3. Rudin
    Rudin
  4. Yang
    Yang
  5. O'Reilly
    O'Reilly
  6. Panageas
    Panageas
  7. Scheinberg
    Scheinberg

Groups

  1. Center for Molecular Imaging and Biotechnology (7)
  2. Department of Medicine (7)
  3. GSK Faculty (7)
  4. Adult Leukemia (5)
  5. Center for Hematologic Malignancies (5)
  6. Hematologic Malignancies, Division of (5)
  7. Executive Committee, Center for Hematologic Malignancies (4)
  8. Human Oncology and Pathogenesis Program (4)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  10. Solid Tumor Oncology Division (3)
Search Within
  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Meeting Abstract (7)
Groups
  1. Center for Molecular Imaging and Biotechnology (7)
  2. Department of Medicine (7)
  3. GSK Faculty (7)
  4. Adult Leukemia (5)
  5. Center for Hematologic Malignancies (5)
  6. Hematologic Malignancies, Division of (5)

More Groups

People
  1. Ross Levine (4)
  2. Charles Rudin (2)
  3. Li Yang (2)
  4. Richard Koche (2)
  5. David Scheinberg (1)
  6. Katherine Panageas (1)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2020 (3)
Publishers
  1. S. Karger AG (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Durvalumab (D) + platinum-etoposide (EP) in 1L extensivestage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; Stewart, R.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • 1L durvalumab (D) + platin-etoposid (EP) beim fortgeschrittenen kleinzelligen lungenkarzinom (ES-SCLC): Explorative analyse der molekularen SCLC-subtypen in der caspian-studie
    Meeting Abstract

    Schulz, C.; Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 22965270 Unknown
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG